Ocugen completes dosing in phase 2/3 trial for Stargardt disease therapy

April 1, 2026 7:02 AM

Ocugen Inc. (NASDAQ: OCGN) announced the completion of dosing in its Phase 2/3 GARDian3 pivotal confirmatory trial for OCU410ST, a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found